Opinión Quiral 39.2: Terapia génica
2019
Advances in DNA editing have meant that gene therapy has gone from being merely a possibility to an incipient reality which is beginning to be used in the treatment of certain diseases. However, there is still some debate as to where the limits of its application lie. The idea is to aim for a transparent, safe and prudent application which guarantees the principles of self-determination and beneficiality, or non-disadvantageousness.
Taking part in this second Chiral Opinion on gene therapy were experts in genetics such as Dr Eduardo Fidel Tizzano (head of Genetic Medicine at the Vall d’Hebron Instituto de Investigación, VHIR), who explained to attendees how over the last few years gene therapy has moved from the experimental stage to clinical practice. Despite the challenges, he was optimistic about future possibilities arising from these new techniques. Also taking part was Núria Terribas (director of the Fundació Víctor Grífols i Lucas), who emphasised how bioethics is trying to find answers to the questions arising from the application of this new technology. She made special mention of the manipulation of DNA without any therapeutic end and how this is a red line which should not be crossed.
Also taking part in the debate were specialist medical journalists and other professionals from the media and medicine. The effectiveness of organisations such as the Comité de Bioética de España and the Comité de Fecundación Asistida was questioned. While applauding the advances made by scientists, the lack of ethical guidelines for research was highlighted. Also explained was a project on neural improvements and how the general public participated in the ethical debate by contributing their criteria, followed by contributions from other doctors attending, who mentioned the possibility of combining gene therapy with stem cell research and immunotherapy in order to push research forward. Apart from the scientific aspect, questions were asked about the possibilities of these therapies reaching the general public, and any savings that could be made by the health system by avoiding lengthy and expensive courses of treatment.
Finally, it was pointed out that there is no healthcare specialisation in genetics in Spain, which would train professionals who would act as a filter when communicating to patients the most relevant information when it came to making an informed decision.
Descarregar